African horse sickness (AHS 1 ) is typically a highly fatal disease in susceptible horses and vaccination is currently used to prevent the occurrence of disease in endemic areas. Similarly, vaccination has been central to the control of incursions of African horse sickness virus (AHSV 2 ) into previously unaffected areas and will likely play a significant role in any future incursions. Horses in the AHSVinfected area in South Africa are vaccinated annually with a live-attenuated (modified-live virus [MLV 3 ]) vaccine, which includes a cocktail of serotypes 1, 3, 4 (bottle 1) and 2, 6, 7, 8 (bottle 2) delivered in two separate doses at least 21 days apart. In this study, the neutralising antibody response of foals immunized with this polyvalent MLV AHSV vaccine was evaluated and compared 1 African horse sickness 2 African horse sickness virus 3 modified-live virus to the response elicited to monovalent MLV AHSV serotypes. Naïve foals were immunized with either the polyvalent MLV AHSV vaccine, or a combination of monovalent MLV vaccines containing individual AHSV serotypes 1, 4, 7 or 8. There was a marked and consistent difference in the immunogenicity of individual virus serotypes contained in the MLV vaccines. Specifically, foals most consistently seroconverted to AHSV-1 and responses to other serotypes were highly variable, and often weak or not detected. The serotype-specific responses of foals given the monovalent MLV vaccines were similar to those of foals given the polyvalent MLV preparation suggesting that there is no obvious enhanced immune response through the administration of a monovalent vaccine as opposed to the polyvalent vaccine.
and the monitoring of seronegative sentinel horses. No cases of AHS have been detected within a radius of at least 30 km of this farm since the inception of the surveillance programme in 1996. The foals were segregated into groups by gender, and individual foals remained within the same group throughout the study. All foals were identified with a microchip and given the same routine veterinary care, including immunization against equine influenza, tetanus and botulism.
Study design
The 46 foals were randomly assigned to three groups (Group I, II and III) and immunized at specific intervals with eitherpolyvalent or monovalent (AHSV 1, 4, 7, 8) MLV AHS vaccines according to the schedule listed in Table 1 . For preparation of the monovalent MLV AHSV vaccines, AHSV serotypes 1 and 4 were selected as representatives of the MLV strains contained in bottle 1 of the polyvalent MLV preparation, and serotypes 7 and 8 as representatives from bottle 2. As the foals included in this study were from a commercial stud, they were all required to be vaccinated according to the regular MLV polyvalent vaccine regimen prior to the next AHS season to fulfil statutory requirements. It was, therefore, not possible to administer a second immunization of monovalent MLV vaccine to foals in groups II and III. Blood for harvesting of serum was collected from each foal and a blinded approach was used to determine the neutralising antibody titres to all nine AHSV serotypes on days, 56, 112, 196 and 238 after first vaccination.
Vaccine
Foals of Group I were vaccinated subcutaneously with 2 ml of the commercially available polyvalent MLV cell culture-adapted AHSV vaccine (Onderstepoort Biological Products SOC Ltd, Onderstepoort, South Africa) given as two doses 28 days apart. Foals of Group II were initially vaccinated with monovalent MLV AHSV serotype 1 followed by monovalent MLV AHSV serotype 8, 28 days later.
Similarly, foals of Group III were vaccinated at a 28 day interval, initially with monovalent MLV AHSV serotype 4 and 28 days later with serotype 7. The monovalent MLV AHSV serotypes 1, 4, 7 and 8 were prepared and supplied by the manufacturer to contain the same viral load and seed stock viruses as those used in the commercial polyvalent MLV vaccine (Table 1 ) and contained a minimum immunizing dose of 1x10 3 pfu/ml for each serotype and a minimum infectivity titre of the final product of 1x10 3 pfu/ml [6] . 
Serum-virus microneutralisation test
The serum neutralising antibody titre of individual foal sera to each of the nine reference strains of AHSV [4;5] was determined by the serum neutralisation test (SNT 8 ) as previously described [22] .
Briefly, each serum sample was inactivated at 56 °C for 30 min and serum dilutions were made in 8 serum neutralisation test
